Skip to main content
. 2022 Feb 22;12(4):1825–1839. doi: 10.1016/j.apsb.2022.02.014

Figure 7.

Figure 7

Osimertinib and PD-1 blockade produces the synergistic effect on the antitumor activity in the CRC patient and mouse model. (A) Representative images of CD31 (red) and PD-L1 (green) immunostaining and DAPI nuclear staining (blue) of tumors in vehicle group and osimertinib group. (B) Flow cytometry analysis of PD-L1 expression in CD45–CD31+ endothelial cells of tumors in two indicated groups. n = 6. (C) Top, schematic of the workflow for treatment as indicated. Bottom, growth of individual tumors from indicated groups. (D) Kaplan–Meier survival curves of mice treated as indicated. (C, D) n = 5. Statistical analysis by unpaired Student's t-test, one-way ANOVA or log-rank test. Data are presented as mean ± SEM. Scale bar = 100 μm.